THE EFFICACY OF COVID-19 VACCINE AND THE CHALLENGE IN IMPLEMENTING MASS VACCINATION IN INDONESIA
Keywords:Efficacy, Covid-19 vaccine, Mass vaccination, Challenge
Novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 2,38 million deaths and more than 108 million cases confirmed in one year of the pandemic are massive upheavals in social life and economy in the international world. An effective vaccine is needed to prevent further morbidity and mortality. This research aims to identify the challenge in implementing mass vaccination in Indonesia which is related to the efficacy of the COVID-19 vaccine. We retrieve sources from relevant and published articles in Google Scholar, Pubmed, DOAJ and Science Direct of articles up to January 2021. The keywords used for gathering information were listed below. Vaccine efficacy is defined as the proportional reduction of a disease case in a group of vaccinated participants compared with unvaccinated participants. The study of vaccine efficacy is a cohort study that is an important vaccine trial method in the field. It is conducted randomly on a large scale by using a control-placebo. During the trials, the country which used the vaccine needs to maintain and observe the vaccine epidemiology. A trial roadmap is expected to identify the condition of the area epidemiologically. Vaccine efficacy is essential to be observed before implementing the vaccine in society. However, intensive socialization about the advantage of vaccines is mainly needed to prevent irrelevant information in social media about mass vaccination.
Singh M, Nagpal M, Singh V, Sharma A, Dhingra GA, Maman P, et al. Covid-19: epidemiology, pathogenicity and global updates. Int J Appl Pharm 2020;12:16-28.
Wang E, Brar K. COVID-19 in children: an epidemiology study from china. J Allergy Clin Immunol Pract 2020;8:2118–20.
World Health Oranization. Naming the coronavirus disease (COVID-19) and the virus that causes it; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. [Last accessed on 05 May 2021]
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020; 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. [Last accessed on 05 May 2021]
Yamey G, Schaferhoff M, Hatchett R, Pate M, Zhao F, McDade KK. Ensuring global access to COVID-19 vaccines. Lancet 2020;395:1405–6.
Briefing WM. WHO Director-general’s opening remarks at the media briefing on COVID-19. World Heal Organ; 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-12-march-2021
Khan S, Liu J, Xue M. Transmission of SARS-CoV-2, required developments in research and associated public health concerns. Frontiers Med 2020;7:310.
Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Annals Internal Med 2020;173:362–7.
Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in zhejiang province, China, January-March 2020: Retrospective cohort study. BMJ 2020;369. http://dx.doi.org/10.1136
To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2:an observational cohort study. Lancet Infect Dis 2020;20:565–74.
Zhu L, Gong N, Liu B, Lu X, Chen D, Chen S, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in wuhan, China. Eur Urol 2020;77:748–54.
Loeliger E, Chaudhari A. Article: COVID-19 efficacy endpoints in interventional trials: what constitutes an incident clinical disease case and what triggers diagnostic work-Up V2.0 • Epidemic Preparedness Innovations. Global Health Network; 2020. Available from: https://epi.tghn.org/articles/covid-19-efficacy-endpoints-interventional-trials-v20/. [Last accessed on 05 May 2021]
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infectious Diseases 2021;21:e26–35.
World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines; 2020. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. [Last accessed on 05 May 2021]
Weinberg GA, Szilagyi PG. Vaccine epidemiology: Efficacy, effectiveness, and the translational research roadmap. J Infectious Diseases 2010;201:1607–10.
U. S. Department of Health and Human Services. Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry; 2020. Available from: https://www.fda.gov/regulatory. [Last accessed on 05 May 2021]
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. Br Med J; 2020. Available from: https://isaric4c.net. [Last accessed on 05 May 2021]
Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 vaccines at pandemic speed. N Engl J Med 2020;382:1969–73.
Dean NE, Gsell PS, Brookmeyer R, De Gruttola V, Donnelly CA, Halloran ME, et al. Design of vaccine efficacy trials during public health emergencies. Sci Transl Med; 2019. Available from: https://pubmed.ncbi.nlm.nih.gov/31270270/. [Last accessed on 05 May 2021]
World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines; 2021. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. [Last accessed on 05 May 2021]
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397:671–81.
Ophinni Y, Hasibuan AS, Widhani A, Matia S, Koesnoe S, Yunihastuti E, et al. COVID-19 vaccines: current status and implication for use in Indonesia | Ophinni | Acta Medica Indonesiana; 2020. Available from: http://www.actamedindones.org/index.php/ijim/article/view/1648/0. [Last accessed on 05 May 2021]
Nugroho A. Pakar UGM: Miliki 65,3 persen efikasi vaksin sinovac tetap aman. Universitas Gadjah Mada; 2021. Available from: https://ugm.ac.id/id/berita/20607-miliki-65-3-persen-efikasi-vaksin-sinovac-aman. [Last accessed on 05 May 2021]
Dharmaningtias DS. Demographic data on the implementation of covid-19 vaccination. Doemstical Political Divison, Info Singkat, A Brief Study of Actual and Strategic Issues; 2021. Available from: https://berkas.dpr.go.id/puslit/files/info_singkat/Info%20Singkat-XIII-3-I-P3DI-Februari-2021-207-EN.pdf. [Last accessed on 08 May 2021]